An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 to <18 years of age with atopic dermatitis

Trial Profile

An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 to <18 years of age with atopic dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Oct 2016 Planned number of patients changed from 80 to 69.
    • 26 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
    • 26 Oct 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top